Loading...
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
SFOSF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$1.96
$0.005(0.26%)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) Financial Performance & Income Statement Overview
Review Shanghai Fosun Pharmaceutical (Group) Co., Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-0.80%
↓ 0.80%
Operating Income Growth
28.35%
↑ 28.35%
Net Income Growth
16.08%
↑ 16.08%
Operating Cash Flow Growth
31.13%
↑ 31.13%
Operating Margin
10.82%
↑ 10.82%
Gross Margin
46.45%
↑ 46.45%
Net Profit Margin
7.27%
↑ 7.27%
ROE
6.18%
↑ 6.18%
ROIC
5.28%
↑ 5.28%
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) Income Statement & Financial Overview
Review Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s (SFOSF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $10.16B | $10.45B | $10.23B | $10.06B |
| Cost of Revenue | $5.48B | $5.43B | $5.74B | $5.08B |
| Gross Profit | $4.68B | $5.02B | $4.50B | $4.99B |
| Gross Profit Ratio | $0.46 | $0.48 | $0.44 | $0.50 |
| R&D Expenses | $996.32M | $786.30M | $937.02M | $829.57M |
| SG&A Expenses | $3.23B | $6.60B | $2.85B | $3.26B |
| Operating Expenses | $3.54B | $3.84B | $3.82B | $4.08B |
| Total Costs & Expenses | $9.02B | $9.27B | $9.55B | $9.16B |
| Interest Income | $93.50M | $90.74M | $304.51M | $87.14M |
| Interest Expense | $364.04M | $358.33M | $361.45M | $348.09M |
| Depreciation & Amortization | $0.00 | $320.39M | $756.64M | $663.29M |
| EBITDA | $1.46B | $1.50B | $1.27B | $1.79B |
| EBITDA Ratio | $0.14 | $0.14 | $0.12 | $0.18 |
| Operating Income | $1.14B | $1.18B | $680.04M | $904.51M |
| Operating Income Ratio | $0.11 | $0.11 | $0.07 | $0.09 |
| Other Income/Expenses (Net) | -$39.80M | -$37.94M | -$278.26M | -$2.94M |
| Income Before Tax | $1.10B | $1.14B | $401.78M | $688.10M |
| Income Before Tax Ratio | $0.11 | $0.11 | $0.04 | $0.07 |
| Income Tax Expense | $103.79M | $171.58M | $149.27M | $232.20M |
| Net Income | $759.24M | $785.84M | $615.06M | $609.73M |
| Net Income Ratio | $0.07 | $0.08 | $0.06 | $0.06 |
| EPS | $0.29 | $0.30 | $0.23 | $0.23 |
| Diluted EPS | $0.29 | $0.30 | $0.23 | $0.23 |
| Weighted Avg Shares Outstanding | $2.66B | $2.66B | $2.67B | $2.67B |
| Weighted Avg Shares Outstanding (Diluted) | $2.66B | $2.66B | $2.67B | $2.67B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan